Summary
This study compared the efficacy of spiramycin with that of amoxicillin in treating patients with acute community-acquired upper respiratory tract infections (URTIs). The study was an open, randomised, comparative parallel design and patients received either spiramycin 3 MIU (2 tablets, 500mg or 1.5 MIU per tablet) twice daily after meals, i.e. 6 MIU/day for 7 days or amoxicillin (500 mg/capsule) 1 capsule three times daily after meals, i.e. 1500 mg/day for 7 days. Patients attending the ENT outpatient clinic at Siriraj Hospital in Bangkok for treatment of acute URTIs were included in the study after giving their informed consent. Eligible patients comprised those aged 18 years and over, of either gender, who had at least two of the following symptoms: fever (≥38°C oral), nasal discharge/obstruction, sore throat, cough and/or hoarseness of voice that did not require parenteral drug therapy or hospitalisation. A total of 99 patients were included in this study, 49 patients received spiramycin and 50 received amoxicillin. Of the 45 assessed patients treated with spiramycin, 40 were judged by the investigators as a ‘success’ (89%), and five were judged a ‘non-success’ (11%), compared with 48 assessed patients in the amoxicillin group where 40 patients were classified as a ‘success’ (83.3%) and 8 were judged a ‘non-success’ (16.7%). No statistically significant differences between treatments were demonstrated regarding the overall efficacy of treatment.
This study demonstrated that the prescribed regimens of spiramycin and amoxicillin were similarly effective in the treatment of adult acute URTIs. The tolerability of both drugs was also similar. Furthermore, it was noted that the convenient twice-daily dosage regimen of spiramycin may allow better patient compliance.
Similar content being viewed by others
References
Public Health Statistics, AO. Division of Epidemiology, Office of the Permanent Secretary for Public Health, Ministry of Public Health, Bangkok, Thailand. Published in the Annual Epidemiological Surveillance Report, 1994
Kernbaum S. Spiramycin therapeutic use in man [English translation]. Semaine des Hopitaux 1982; 58(5): 289–97
Bergogne-Berezin E. Spiramycin concentrations in the human respiratory tract: a review. J Antimicrob Chemother 1988; 22 Suppl. B: 117–22
Chavanet P, Portier H. Treatment of acute pharyngitis. Rev Prat [Paris] 1992; 42(3): 303–7
Kamme C, Kahlmeter G, Melander A. Evaluation of spiramycin as a therapeutic agent for elimination of nasopharyngeal pathogens. Scand J Infect Dis 1978; 10: 135–42
Dabernat H, Delmas C. In. vitro inhibitory activity of spiramycin against Haemophilus influenzae. In: Sabbour MS, Cocuzza G, editors. Proceedings of the V Mediterranean Congress of Chemotherapy, 26 October-1 November 1986, Cairo, Egypt. Chemioterapia 1987; 6 (2 Suppl.): 158-9
Derrienic M, Dubreuil L, Reynaud AE, et al. Comparitive in vitro activities of four macrolides: josamycin, erythromycin, spiramycin and roxithromycin, against 424 anaerobic bacteria. Chemioterapia 1987; 6(2 Suppl.): 159–60
Webster C, Ghazanfar K, Slack R. Sub-inhibitory and post-antibiotic effects of spiramycin and erythromycin on Staphylococcus aureus. J Antimicrob Chemother 1988; 22 Suppl. B: 33–9
Manolopoulos L, Adamopoulos C, Tzagaroulakis A, et al. Spiramycin versus penicillin V in the empirical treatment of bacterial tonsillitis. Br J Clin Pract 1989; 43(3): 94–6
Boezman AJ, Kayser AM, Siemelink RJG. Comparison of spiramycin and doxycycline in empirical treatment of acute sinusitis. J Antimicrob Chemother 1988; 22 Suppl. B: 165–70
Dellamonica P. Treatment of acute bronchitis. Rev Prat Med Gen 1992; 167: 1–6
Walstad RA, Thurmann-Nielsen E, Jetlund O. Predicting spiramycin efficacy in pneumonia and tonsillitis. Abstract book of the 7th International Congress for Infectious Diseases [abstract no. 6005]. 1996 June 10–13: Hong Kong: 8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bunnag, C., Jareoncharsri, P., Voraprayoon, S. et al. Efficacy of Spiramycin as an Alternative to Amoxicillin in the Treatment of Acute Upper Respiratory Tract Infections. Clin. Drug Investig. 15, 461–466 (1998). https://doi.org/10.2165/00044011-199815060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199815060-00001